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Amyotrophic lateral sclerosis (ALS) is the commonest clinical form of the wider neu-rodegenerative syndrome encompassed by the term motor neuron disease (MND). ALS has a consistent incidence of 1-2/100,000/year, and a lifetime risk estimated at 1 in 400. The disease is characterized by the progressive death of upper motor neurons 
(UMNs) of the cerebral primary motor cortex and corticospinal tract, in combination with degen-
eration of lower motor neurons (LMNs) whose origins lie in the brainstem and spinal anterior 
horns. Loss of motor neurons in general results in weakness, but specifically loss of LMNs results 
in secondary wasting of the downstream musculature and spasticity arises from loss of UMNs1.
About 10% of cases are considered as being familial ( fALS), whereas the remaining 90% seem 
to occur sporadically (sALS) with no family history of ALS. Since the first discovery of SOD1 
mutations being causative for ALS in 19932, researchers all over the world have made great effort 
to further delineate the genetic basis underlying ALS. Today, more than 30 confirmed major dis-
ease genes are listed by the Amyotrophic Lateral Sclerosis Online genetics Database (ALSoD), 
the most frequently affected being C9orf72 (40% fALS, 5–6% sALS; pathogenic repeat expan-
sion in the non-coding region between exons 1a and 1b, detection by repeat analysis), SOD1 
(20% fALS, 3% sALS), FUS (5% fALS, <1% sALS) and TARDBP (3% fALS,2% sALS)3.
In addition to this clinically heterogeneous syndrome a pathologically overlapping with 
frontotemporal dementia motor signs have been detected by neuropsychological tests in 
about 50% of sALS patients. Furthermore typical frontotemporal dementia (FTD) occurs in 
approximately 10% of the patients4, and the term frontotemporal dementia-motor neuron dis-
ease (FTD-MND) continuum was proposed to describe this association4, which occurs mostly 
in C9ORF72-linked fALS5.
Despite all this clinical and etiopathogenic complexity, some faces of ALS, including FTD-MND 
continnum, have been elucidated by magnetic resonance imaging (MRI) techniques, which have 
proved to be useful to reveal microstructural brain abnormalities associated with different rates 
of symptom progression6,7. A plausible biomarker for upper motor neuron degeneration in ALS is 
becoming tangible after recent advances in high-throughput MRI techniques, through which one 
can believe that we are going to the forefront of a breakthrough able to translate research findings 
into reliable clinical tests that will support the practice of  personalized medicine8,9,10.
Advances in neuroimaging have enabled mapping of some endpoints in functional, struc-
tural, and molecular aspects of ALS pathology. Menke et al.8 have recently reported imaging 
abnormalities even before clinical symptoms, offering the potential for neuroprotective inter-
vention, particularly in familial cases. Current literature points to DTI technique as the most 
promising candidate for imaging biomarker in ALS, able to elucidate the brain phenotype of 
ALS and also detect white matter tract changes in extramotor regions8,10. 
The results of Chaves et al.11 using a 1.5 Tesla MR equipment reinforce the clinical use of 
fractional anisotropy (FA) to detect extra-motor brain abnormalities in ALS patients. Despite 
this further multicenter validation with larger cohorts of patients remains mandatory prior to 
the integration of this technique into the clinical routine as biomarker able to contribute in 
standard clinical decision-making algorithms.
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